Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;184(4):746-748.
doi: 10.1111/bjd.19629. Epub 2020 Dec 1.

Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-programmed-death-receptor-1 monoclonal antibodies

E Charvet  1 , N Kramkimel  2 , L Chaplain  1   3 , A Gantzer  1 , O Kassem  1 , C Longvert  1   3 , A Blom  1   3 , N Dupin  2 , S Aractingi  2 , M Hamon  4 , U Zimmermann  4 , J-F Emile  3   4 , P Sohier  5 , T Sidibé  6 , P Saiag  1   3 , E Funck-Brentano  1   3
Affiliations

Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-programmed-death-receptor-1 monoclonal antibodies

E Charvet et al. Br J Dermatol. 2021 Apr.
No abstract available

PubMed Disclaimer

References

    1. Perier-Muzet M, Thomas L, Poulalhon N et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol 2014; 134:1351-8.
    1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018; 378:158-68.
    1. Hua C, Boussemart L, Mateus C et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152:45-51.
    1. Freites-Martinez A, Kwong BY, Rieger KE et al. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol 2017; 153:694-7.
    1. Jones MS, Torisu-Itakura H, Flaherty DC et al. Second primary melanoma: risk factors, histopathologic features, survival, and implications for follow-up. Am Surg 2016; 82:1009-13.

MeSH terms

Substances